MORE►
biotech
[Sources: suksunt sansawast/Kolonko/arthobbit/istockphoto; DI Studio]
North Texas’ EnLiSense Develops Wearable Sensor That Uses Sweat to Track Sleep Hormones
by Maddie Preston | Feb 3, 2026
A UT Dallas study supports Allen-based EnLiSense’s approach to circadian health monitoring, via a wearable that directly measures biochemical markers tied to wakefulness and sleep.
by Sandra Engelland |
Dec 30, 2025
The Fort Worth oncology company tapped former Salarius Pharmaceuticals CEO David Arthur to lead its push toward commercialization, including a planned IND for a rare pediatric brain cancer program.
MORE►
by Maddie Preston |
Dec 23, 2025
A new satellite campus is adding hands-on training, lab capacity and startup support to Dallas’ growing life sciences ecosystem.
MORE►
by Quincy Preston |
Nov 5, 2025
Cait Brumme says the event at Dallas' Pegasus Park on Nov. 6 will explore the technologies and economic forces defining the future for entrepreneurs and innovators.
MORE►
Hans Gangeskar, CEO of Overture Life [Composite image; Original photo: Hans Gangeskar/LinkedIn]
Overture Life Opens Its First U.S. IVF Robotics Clinical Lab and Operations Hub in Dallas
by David Seeley | Oct 23, 2025
The Palo Alto-based company's new Dallas facility is its first dedicated U.S. laboratory, and will serve as its U.S. clinical operations headquarters. Overture's AI-driven IVF technology gives fertility teams "objective data to inform embryo selection without a biopsy," the company said, "allowing clinics to process three times the number of procedures without adding staff."
MORE►
by Quincy Preston |
Oct 14, 2025
The North Texas biotech, which uses AI to accelerate cancer drug development, received FDA feedback to advance a new clinical study targeting a rare childhood brain tumor.
MORE►
by Maddie Preston |
Sep 27, 2025
The UTD team’s approach adapts a chip-security technique to biology. The breakthrough gives biotech companies a new way to prevent costly misidentification and protect intellectual property.
MORE►
by Glenn Hunter |
Sep 24, 2025
At Dallas’ iC3 Summit, leaders from Texas and across the U.S. pointed to AI, new state initiatives like Proposition 14, and potential federal reforms as keys to speeding innovation and keeping America competitive in life sciences.
MORE►
[Image: istockphoto]
The Last Word: Tech FW on How Nanoscope’s ‘Watch Us’ Moment Could Help Blind Patients See Again
by Quincy Preston | Jul 15, 2025
North Texas' Nanoscope just filed an FDA bid for its gene-agnostic therapy. If approved, it could help restore sight for people with inherited blindness, and potentially millions more with other retinal diseases.
MORE►
by David Seeley |
Jul 15, 2025
The California-based clinical-stage biotech startup is developing therapies to treat serious immunological diseases like atopic dermatitis and vitiligo.
MORE►
![The South Island giant moa towered over New Zealand's forests for millions of years before becoming extinct within a century of Polynesian settlement around 1400 CE. Colossal Biosciences plans to resurrect the 500-pound birds using ancient DNA extracted from cave deposits and artificial egg technology. [Source image: Colossal Biosciences]](https://s24806.pcdn.co/wp-content/uploads/2025/07/Colossal-Moa-360x203.jpg)
by Quincy Preston |
Jul 9, 2025
The Dallas decacorn is scaling its de-extinction pipeline with indigenous leadership, a New Zealand subsidiary, and economic models for species preservation, including ecotourism opportunities. Filmmaker Sir Peter Jackson helped connect the collaborators, Colossal CEO Ben Lamm says.
MORE►
by Lance Murray |
Jun 5, 2025
Co-founded by Chief Scientific Advisor Daniel J. Siegwart of UT Southwestern and CEO RA Session II, Signify Bio said it harnesses the human body for the production of in situ protein therapeutics. The round was led by Actium Group with participation from the Gates Foundation Strategic Investment Fund, Danaher Ventures LLC, Eli Lilly and Company, and BrightEdge, the American Cancer Society's VC arm.
MORE►
GenrAb CEO Larry Tiffany, who is leading the company's push to bring a first-in-class neuroprotective therapy into the clinic, also serves as Executive Chairman and Director at Medcura. [Sources: Medcura photo; iStock background; DI Studio]
UT Southwestern Spinout Emerges From Stealth With $5.6M to Push ‘First in Class’ Neuroprotective Therapy Into the Clinic
by Quincy Preston | Apr 24, 2025
Dallas biotech GenrAb is developing an antibody therapy that aims to protect brain cells under stress—the kind of damage that leads to disability in diseases like MS and ALS. The therapy, found in the spinal fluid of real patients, is now showing promise in animal models and moving toward human trials.
MORE►
by Lance Murray |
Apr 8, 2025
With the new funding, Caris said it has raised $1.86 billion in capital since 2018. Caris will use the raise to bring its science and technologies "to as many patients as possible and further our goal of revolutionizing precision medicine," Founder and CEO David Halbert said.
MORE►
by Quincy Preston |
Apr 7, 2025
“Game of Thrones” made them famous, but the prehistoric dire wolves were real—and, according to Colossal Biosciences, have now returned after 12,500 years in what it calls the world’s first successful de-extinction. The work goes beyond headlines: It could change how we save endangered species.
Meet Romulus, Remus, and Khaleesi in a video—and hear dire wolf howls for the first time in more than 12 millennia.
MORE►
by Nicole Ward, DRC Data Journalist |
Mar 27, 2025
Eido Bio’s three co-founders are taking on menopause, research gaps, and a market where women’s health “sort of starts and stops with birth control.” The biotech startup is raising a Series A to launch clinical trials for a menopause treatment—and help shift the science toward women.
MORE►
